Literature DB >> 30218782

Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function.

Sophia Kogan1, Luz H Ospina1, David Kimhy2.   

Abstract

Individuals with schizophrenia display substantial deficits in neurocognition, resulting in poor daily functioning and disability. Recent reports have suggested that neurocognitive dysfunction in this population is linked to increased inflammation. However, there is paucity of evidence supporting this link, as well as lack of information about the putative link of inflammation to daily functioning. We examined neurocognition (MCCB) and daily functioning (SLOF), as well as inflammatory markers (TNF-α, IL-6, IL-1β, and IL-12p70) in 41 individuals with schizophrenia. Poor neurocognition was significantly associated with increased peripheral TNF-α and IL-12p70 (r = -0.44 and r = -0.38, respectively, controlling for BMI, depression and antipsychotic medication). Notably, difficulties with daily functioning were significantly associated with increased peripheral TNF-α (r = -0.51) and a trend with increased IL-12p70. Our findings support previous hypotheses linking neurocognitive impairment to increased inflammation in individuals with schizophrenia. Our results extend these associations in this population, linking inflammation to poor daily functioning in this population.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Daily functioning; IL-12-p70; IL-1β; IL-6; Inflammation; Neurocognition; Schizophrenia; TNF-α

Mesh:

Substances:

Year:  2018        PMID: 30218782      PMCID: PMC6805148          DOI: 10.1016/j.bbi.2018.09.016

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  32 in total

Review 1.  Blood-brain barrier transport of cytokines: a mechanism for neuropathology.

Authors:  William A Banks
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

2.  Interaction between BDNF and TNF-α genes in schizophrenia.

Authors:  Yi Zhang; Xinyu Fang; Weixing Fan; Wei Tang; Jun Cai; Lisheng Song; Chen Zhang
Journal:  Psychoneuroendocrinology       Date:  2017-12-29       Impact factor: 4.905

Review 3.  Regulation of tumour necrosis factor signalling: live or let die.

Authors:  Dirk Brenner; Heiko Blaser; Tak W Mak
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

4.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

5.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

6.  TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia.

Authors:  David R Goldsmith; Ebrahim Haroon; Andrew H Miller; Gregory P Strauss; Peter F Buckley; Brian J Miller
Journal:  Schizophr Res       Date:  2018-02-28       Impact factor: 4.939

7.  Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits.

Authors:  Julia Vakhrusheva; Brielle Marino; T Scott Stroup; David Kimhy
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-04

Review 8.  Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction.

Authors:  Keigan M Park; William J Bowers
Journal:  Cell Signal       Date:  2010-01-21       Impact factor: 4.315

9.  The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.

Authors:  Richard S E Keefe; Margaret Poe; Trina M Walker; Philip D Harvey
Journal:  J Clin Exp Neuropsychol       Date:  2006-02       Impact factor: 2.475

10.  Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning.

Authors:  David Kimhy; Julia Vakhrusheva; Matthew N Bartels; Hilary F Armstrong; Jacob S Ballon; Samira Khan; Rachel W Chang; Marie C Hansen; Lindsey Ayanruoh; Edward E Smith; Richard P Sloan
Journal:  Psychiatry Res       Date:  2014-09-03       Impact factor: 3.222

View more
  11 in total

1.  Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia.

Authors:  Luz H Ospina; Melanie Wall; Lars F Jarskog; Jacob S Ballon; Joseph McEvoy; Matthew N Bartels; Richard Buchsbaum; Richard P Sloan; T Scott Stroup; David Kimhy
Journal:  J Psychiatr Brain Sci       Date:  2019-12-30

2.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

3.  Inflammation and emotion regulation: Findings from the MIDUS II study.

Authors:  Luz H Ospina; Katie Beck-Felts; Chloe Ifrah; Amanda Lister; Sylvie Messer; Scott J Russo; James J Gross; David Kimhy
Journal:  Brain Behav Immun Health       Date:  2022-10-10

4.  A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia.

Authors:  Egor Chumakov; Mariia Dorofeikova; Kristina Tsyrenova; Nataliia Petrova
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

Review 5.  The impact of inflammation on neurocognition and risk for psychosis: a critical review.

Authors:  Sophia Kogan; Luz H Ospina; Vijay A Mittal; David Kimhy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-10-16       Impact factor: 5.270

6.  The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia.

Authors:  Xiaoyan He; Qingyan Ma; Yajuan Fan; Binbin Zhao; Wei Wang; Feng Zhu; Xiancang Ma; Lina Zhou
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-21       Impact factor: 2.570

7.  TGF-β1 is associated with deficits in cognition and cerebral cortical thickness in first-episode schizophrenia.

Authors:  Shujuan Pan; Yanfang Zhou; Ling Yan; Fangling Xuan; Jinghui Tong; Yanli Li; Junchao Huang; Wei Feng; Song Chen; Yimin Cui; Fude Yang; Shuping Tan; Zhiren Wang; Baopeng Tian; L Elliot Hong; Yun-Long Tan; Li Tian
Journal:  J Psychiatry Neurosci       Date:  2022-03-17       Impact factor: 5.699

8.  Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls.

Authors:  David R Goldsmith; Nicholas Massa; Bradley D Pearce; Evanthia C Wommack; Alaaeddin Alrohaibani; Neha Goel; Bruce Cuthbert; Molly Fargotstein; Jennifer C Felger; Ebrahim Haroon; Andrew H Miller; Erica Duncan
Journal:  NPJ Schizophr       Date:  2020-04-01

9.  Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China.

Authors:  Xia Wen; Xusan Xu; Xudong Luo; Jinwen Yin; Chunmei Liang; Jinyuan Zhu; Xueyan Nong; Xiudeng Zhu; Fan Ning; Shanshan Gu; Susu Xiong; Jiawu Fu; Dongjian Zhu; Zhun Dai; Dong Lv; Zhixiong Lin; Juda Lin; You Li; Guoda Ma; Yajun Wang
Journal:  Psychiatr Genet       Date:  2021-08-01       Impact factor: 2.458

Review 10.  Cytokine Alterations in Schizophrenia: An Updated Review.

Authors:  Sara Momtazmanesh; Ameneh Zare-Shahabadi; Nima Rezaei
Journal:  Front Psychiatry       Date:  2019-12-06       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.